Clinical Trial

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-03-11; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2023-07-25
Trial Details
NCT Number NCT04796545
Lead Sponsor VisionCare, Inc.
Conditions AMD, Age-Related Macular Degeneration
Enrollment 76 participants
Start Date 2022-09-13
Primary Completion 2027-02 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-10